



an Open Access Journal by MDPI

Evaluation of the Antitumor Mechanism of Armed Antibodies

Guest Editors:

Dr. Yoshikatsu Koga

Department of Strategic
Programs, Exploratory Oncology
Research & Clinical Trial Center
(EPOC), National Cancer Center,
Kashiwa, Japan

Dr. Hiroki Takashima

Division of Developmental
Therapeutics, Exploratory
Oncology Research & Clinical
Trial Center (EPOC), National
Cancer Center, Kashiwa, Japan

Dr. Shigehiro Koganemaru

Department of Experimental
Therapeutics, National Cancer
Center Hospital East, Kashiwa,
Japan

Deadline for manuscript
submissions:

closed (31 October 2022)

Message from the Guest Editors

After this success in obtaining target-specific mAbs easily, the “missile therapy” or the “immunoconjugate” was developed for clinical use in the late 1980s. In the 1990s, antibody engineering technologies that allowed genetic modification of murine antibodies to produce chimeric mouse–human antibodies or humanized antibodies were developed. From the late 2000s, these mAbs were again applied to the immunoconjugate, named the “antibody drug conjugate”. ADCs are categorized as armed antibodies, which means antibodies have the “weapons”, and antibodies are used for delivery carriers of the weapons, such as anticancer drugs and radioisotopes. As of August 2020, 9 ADCs and one radioimmunotherapy (RIT) drug have been approved by the FDA. Thus, armed antibodies are one of the most exciting areas for cancer therapeutics. In this Special Issue of Pharmaceuticals, original research, mini-review, and review articles regarding armed antibodies are invited. This Special Issue focuses on the therapeutic antibodies in vitro, in vivo, and clinical studies.



mdpi.com/si/59173

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com